LASIK outcomes comparing vector planning to manifest refraction for the treatment of myopic astigmatism

Session Details

Session Title: LASIK Outcomes and Refinements

Session Date/Time: Monday 09/10/2017 | 14:30-15:50

Paper Time: 15:19

Venue: Room 4.4

First Author: : G. Stamatelatos AUSTRALIA

Co Author(s): :    N. Alpins    J. Ong                 

Abstract Details

Purpose:

To investigate refractive astigmatism outcomes including the ocular residual astigmatism (ORA) using excimer laser treatments based on vector planning compared to manifest refraction alone.

Setting:

NewVision Clinics, Melbourne, Australia

Methods:

Prospective study was performed on 160 consecutive eyes undergoing refractive laser surgery for myopic astigmatism on the Schwind Amaris Total-Tech laser with Ziemer LDV femtosecond laser for flap creation. The first 80 eyes were treated using vector planning (VP), which incorporates the corneal astigmatism as well as the manifest refractive astigmatism into the treatment plan with 60% emphasis placed on the correction of refractive cylinder and 40% emphasis based on the correction of corneal astigmatism. The last 80 eyes were treated using the manifest refraction alone (MR). Inclusion criteria were based on an ocular residual astigmatism (ORA) of > 0.75D.

Results:

6 months postoperatively, the VP group had 97% of eyes < 0.25D of refractive cylinder compared with 92% for the MR group. 96% of eyes in VP group versus 93% in MR group had UDVA of 20/20 or better. 75% of eyes in VP group had corneal astigmatism of < 0.75D compared with 34% in the MR group. Postoperatively the ORA was 1.06D for the MR group and 0.71D for the VP group. Total astigmatism postoperatively for the MR group was 1.12D and 0.81D for the VP group.

Conclusions:

Excimer laser treatments using vector planning resulted in less corneal astigmatism, less refractive cylinder and total astigmatism, and better unaided visual acuity postoperatively than treatments using manifest refractive treatment parameters alone.

Financial Disclosure:

gains financially from product or procedure presented